High Resolution Crystal Structure of the Pyruvate Kinase Tetramer in Complex with the Allosteric Activator Mitapivat/AG-348

被引:0
|
作者
Han, Xiao [1 ,2 ]
Sandalova, Tatyana [1 ,2 ]
Zhang, Cheng [3 ]
Mardinoglu, Adil [3 ,4 ]
Achour, Adnane [1 ,2 ]
Sun, Renhua [1 ,2 ]
机构
[1] Karolinska Univ Hosp, Dept Med Solna, Karolinska Inst, Sci Life Lab, S-17165 Stockholm, Sweden
[2] Karolinska Univ Hosp, Div Infect Dis, S-17165 Stockholm, Sweden
[3] KTH Royal Inst Technol, Dept Prot Sci, Sci Life Lab, S-17121 Stockholm, Sweden
[4] Kings Coll London, Fac Dent Oral & Craniofacial Sci, Ctr Host & Microbiome Interact, London SE1 9RT, England
关键词
human pyruvate kinase; PK deficiency; Mitapivat; crystal structure; DEFICIENCY; SITE; M2;
D O I
10.3390/cryst14050441
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
Pyruvate kinase (PK) deficiency is a rare genetic disorder that affects this critical enzyme within the glycolysis pathway. In recent years, Mitapivat (MTPV, AG-348) has emerged as a notable allosteric activator for treating PK deficiency. However, the allosteric regulatory effects exerted on PK by MTPV are yet to be comprehensively elucidated. To shed light on the molecular mechanisms of the allosteric effects, we employed crystallography and biophysical methods. Our efforts yielded a high-resolution crystal structure of the PK tetramer complexed with MTPV at 2.1 & Aring; resolution. Isothermal titration calorimetry measurements revealed that MTPV binds to human PK with an affinity of 1 mu M. The enhanced structural details now allow for unambiguous analysis of the MTPV-filled cavity intricately embedded within the enzyme. Finally, the structure suggests that MTPV binding induces an allosteric effect on the B-domain situated proximal to the active site. In summary, our study provides valuable insights into the allosteric regulation of PK by MTPV and paves the way for further structure-based drug optimization for therapeutic interventions in PK deficiency.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (ACTIVATE) in Progress
    van Beers, Eduard J.
    Judge, Malia P.
    Hua, Lei
    Mix, Chris
    BLOOD, 2019, 134
  • [22] Genotype-Response Correlation in DRIVE PK, a Phase 2 Study of AG-348 in Patients with Pyruvate Kinase Deficiency
    Kung, Charles
    Kosinski, Penelope A.
    Mangus, Heidi
    Hua, Lei
    Connor, Gary
    Mobilia, Michelle
    Sullivan, Karen
    Frye, Sasha
    Jouvin, Marie-Helene
    Grace, Rachael F.
    Glader, Bertil
    Bowden, Chris
    BLOOD, 2018, 132
  • [23] Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency
    Le, Kha
    Cohen, Marvin
    Chen, Yue
    Kim, Hyeryun
    Silver, Bruce
    Agresta, Sam
    Merica, Elizabeth
    Kung, Charles
    Kosinski, Penelope
    Silverman, Lee
    Biller, Scott
    Yang, Hua
    BLOOD, 2015, 126 (23)
  • [24] EX VIVO TREATMENT OF RED BLOOD CELLS FROM 15 PYRUVATE KINASE (PK)-DEFICIENT PATIENTS WITH AG-348, AN ALLOSTERIC ACTIVATOR OF PK-R, INCREASES ENZYMATIC ACTIVITY, PROTEIN STABILITY AND ATP LEVELS.
    van Oirschot, B.
    Kosinski, P. A.
    Hixon, J.
    Johnson, K.
    Chubukov, V.
    Dang, L.
    Pasterkamp, G.
    van Straaten, S.
    Kung, C.
    van Wijk, R.
    HAEMATOLOGICA, 2017, 102 : 241 - 242
  • [25] Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects
    Yang, Hua
    Merica, Elizabeth
    Chen, Yue
    Cohen, Marvin
    Goldwater, Ronald
    Hill, Collin
    Kim, Hyeryun
    Kosinski, Penelope
    Kung, Charles
    Silver, Bruce
    Utley, Luke
    Agresta, Sam
    BLOOD, 2014, 124 (21)
  • [26] Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress
    Kuo, Kevin H. M.
    Layton, D. Mark
    Uhlig, Katrin
    Lynch, Megan
    Liu, Li
    Vichinsky, Elliott P.
    BLOOD, 2019, 134
  • [27] PRECLINICAL PHARMACOKINETICS AND PHARMACODYNAMICS OF AG-519, AN ALLOSTERIC PYRUVATE KINASE-R ACTIVATOR
    Chen, Y.
    Nagaraja, R.
    Le, K.
    Kosinski, P. A.
    Histen, G.
    Kung, C.
    Kim, H.
    Prakash, C.
    Dang, L.
    Popovici-Muller, J.
    Hixon, J.
    Silverman, L.
    Biller, S.
    Yang, H.
    HAEMATOLOGICA, 2016, 101 : 336 - 336
  • [28] Structure-Based Design of AG-946, a Pyruvate Kinase Activator
    Liu, Tao
    Padyana, Anil K.
    Judd, Evan T.
    Jin, Lei
    Hammoudeh, Dalia
    Kung, Charles
    Dang, Lenny
    CHEMMEDCHEM, 2024, 19 (05)
  • [29] Phenotypic Corrections of Ex Vivo Erythrocytes Derived from Chronic Hemolytic Anemia Patients Due to Kruppel-like Factor 1 (KLF-1) Mutations By AG-348: A Novel Synthetic Pyruvate Kinase Activator
    Suksangpleng, Thidarat
    Tachavanich, Kalaya
    Riolueang, Suchada
    Ekwattanakit, Supachai
    Viprakasit, Vip
    BLOOD, 2019, 134
  • [30] CRYSTAL-STRUCTURE OF CAT MUSCLE PYRUVATE-KINASE AT A RESOLUTION OF 2.6 A
    STUART, DI
    LEVINE, M
    MUIRHEAD, H
    STAMMERS, DK
    JOURNAL OF MOLECULAR BIOLOGY, 1979, 134 (01) : 109 - 142